Greater Certainty of Survival Valued Over Speedier Drug Access

The FDA’s accelerated approval pathway allows for quicker access to drugs based on surrogate endpoints, such as progression-free survival. However, when considering new cancer drugs, patients are not always willing to forgo evidence of an overall survival benefit in favor of quicker access, according to a recent study.